Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
TAP Partner Allotera Therapeutics Closes $35 Million Financing to Advance Novel CAR-T Therapy for T-cell Cancers
Allotera Therapeutics partners with the Blood Cancer United Therapy Acceleration Program (TAP) to support development of its off-the-shelf CAR-T thera…
TAP Portfolio Highlights – EHA 2026
At the recent 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden, Blood Cancer United’s Therapy Acceleration Program (TAP) compa…
TAP Partner Solu Therapeutics Receives FDA Fast Track Designation
FDA grants Fast Track designation to STX-0712, an investigational treatment for patients with CMML.
News
FDA Approves a Patient-Friendly, Dissolvable Therapeutic for Chronic Myeloid Leukemia
The dissolvable format may also benefit individuals who have difficulty swallowing pills, offering greater flexibility and ease of use.
News
FDA Approves New Treatment for an Ultra‑Rare, Aggressive Blood Cancer
“This is meaningful for patients with BPDCN, where choices have historically been limited, especially for those whose disease has relapsed or stopped …
News
Blood Cancer United Data at 2026 ASCO and EHA Highlight Beat AML Progress, Patient Experience Insights and Access Barriers
Blood Cancer United-funded researchers will present findings spanning novel treatment approaches and optimization strategies, real-world access and co…
News
Blood Cancer United Opens Applications for the Equity In Access Research Program
Blood Cancer United is now accepting Letters of Intent for its Equity in Access Research Program through September 10, 2026. The 2026 Request for Prop…
News
Blood Cancer United’s Therapy Acceleration Program Receives $1M Grant from Blood Cancer UK
Blood Cancer United is actively growing TAP to increase its portfolio and become self-sustaining while continuing to advance the organization's missio…
News
FDA Approves Oral Combo Treatment for Older Adults with Newly Diagnosed AML
“Older adults make up the majority of people diagnosed with AML, and unfortunately many are not eligible for or cannot tolerate intensive chemotherapy…
News
Blood Cancer United Receives AWS Grant to Expand Use of Generative AI in Beat AML Master Clinical Trial Tool
Grant will scale AI‑driven automation for regulatory documentation to help accelerate clinical research.
News
FDA Expands Approval of Chemoimmunotherapy Combination for People with Classical Hodgkin Lymphoma
Research funded by Blood Cancer United helped establish the importance of the PD‑1 pathway in classical Hodgkin lymphoma—a foundational insight that l…
News
FDA Approves Combination Treatment for Multiple Myeloma
Blood Cancer United has played a long-term role in supporting the foundational research that paved the way for this approval. Over more than a decade,…
